Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine under the Mening A Con brand; and other developed products. It also provides cold storage services. Chongqing Zhifei Biological Products Co., Ltd. was founded in 2002 and is based in Chongqing, China.

Sector

Healthcare

Industry

Biotechnology

CEO

Jiang, Lingfeng

Employees

7,220

Website

www.zhifeishengwu.com

IPO Date

2010-09-28

Headquarters

Building T1, 50th-51st Floor, No. 1 Qingyun Road, Jiangbei District, Chongqing 400020, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.